Havas launched Shape Shifting — its first-ever creator-led, serialized content platform focused on the unfolding GLP-1 revolution — at the 2025 Consumer Electronics Show (CES). By combining medical ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effi ...

BOSTON – A Massachusetts nutritionist has advice for anyone working on having a better diet in 2025. She says rather than restricting what you eat, focus on ways to improve your gut. Gut health has ...

Her doctor was on board, so long as Hasan also agreed to start resistance training—something she had only done briefly in the ...

Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just ...

Metsera's MET-097i shows 11.3% weight loss in Phase 2a trial, beating Wegovy and Zepbound at 3 months, with potential for monthly dosing and no titration requirement.

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

What does the latest science say about the use of GLP-1 meds to treat obesity in people without diabetes?A review of 26 ...

Obesity is a common problem in society at large, but is seen at higher rates among persons living with mental disorders. The ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Financial writer downgrades The Hershey Company (HSY) due to rising cocoa prices and competition, forecasting further share price declines.